Literature DB >> 9395374

Review: JC virus infection of lymphocytes--revisited.

G L Gallia1, S A Houff, E O Major, K Khalili.   

Abstract

JC virus (JCV), the causative agent of the fatal human demyelinating disease progressive multifocal leukoencephalopathy (PML), is an opportunistic papovavirus that infects and destroys oligodendrocytes, the myelin-producing cells of the central nervous system. Since its isolation from the brain of a PML patient, JCV has long been classed as a neurotropic virus. Many studies, however, have demonstrated that JCV can infect various other cell types, including immune system cells. Moreover, several recent studies have focused specifically on lymphocytes as a target of JCV. This review chronicles the association of JCV with lymphocytes, including cell type localization, molecular regulation, and viral sequences, and discusses clinical implications of these findings.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395374     DOI: 10.1086/514161

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy.

Authors:  L A Pfister; N L Letvin; I J Koralnik
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Presence of JC virus DNA in the tumor tissue and normal mucosa of patients with sporadic colorectal cancer (CRC) or with positive family history and Bethesda criteria.

Authors:  Alex Vilkin; Ziv Ronen; Zohar Levi; Sara Morgenstern; Marisa Halpern; Yaron Niv
Journal:  Dig Dis Sci       Date:  2011-08-10       Impact factor: 3.199

3.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Ozgür Yaldizli; Norman Putzki
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 4.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

5.  Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas.

Authors:  B Krynska; L Del Valle; S Croul; J Gordon; C D Katsetos; M Carbone; A Giordano; K Khalili
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 6.  Persistence and pathogenesis of the neurotropic polyomavirus JC.

Authors:  Hassen S Wollebo; Martyn K White; Jennifer Gordon; Joseph R Berger; Kamel Khalili
Journal:  Ann Neurol       Date:  2015-03-06       Impact factor: 10.422

7.  Archetype JC virus efficiently replicates in COS-7 cells, simian cells constitutively expressing simian virus 40 T antigen.

Authors:  K Hara; C Sugimoto; T Kitamura; N Aoki; F Taguchi; Y Yogo
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy.

Authors:  Cesare Giovanni Fedele; Maria Rosa Ciardi; Salvatore Delia; Gerardo Contreras; José Luis Perez; Maria De Oña; Elisa Vidal; Antonio Tenorio
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

Review 9.  Multiple roles for Puralpha in cellular and viral regulation.

Authors:  Martyn K White; Edward M Johnson; Kamel Khalili
Journal:  Cell Cycle       Date:  2009-02-10       Impact factor: 4.534

10.  Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsilar hypertrophy.

Authors:  Atsushi Kato; Tadaichi Kitamura; Tomokazu Takasaka; Takashi Tominaga; Akira Ishikawa; Huai-Ying Zheng; Yoshiaki Yogo
Journal:  J Neurovirol       Date:  2004-08       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.